NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeoGenomics reports robust Q4 earnings, targets profitability in 2023

NeoGenomics delivered strong financial performance in Q4 2022 and full-year 2022, with a focus on sustainable long-term growth. The company aims to achieve adjusted EBITDA positive by Q4 2023 through strategic initiatives, including revenue growth, margin improvement, and operational efficiencies.

NeoGenomics reports robust Q1 results, eyes growth in diagnostics

NeoGenomics' Q1 performance reflects strong revenue growth and operational improvements, driven by strategic priorities and salesforce optimization.
While facing challenges in market share capture and modalities impact, the company's focus on automation and revenue cycle management presents growth opportunities.
Overall, NeoGenomics is well-positioned to achieve its full-year guidance and capitalize on opportunities in advanced diagnostics and revenue optimization.

NeoGenomics excels in Q2, raises guidance on strong growth prospects

NeoGenomics delivered strong financial results, raised revenue guidance, and improved operational efficiencies. With a focus on NGS portfolio expansion, revenue growth, and strategic planning, the company is well-positioned for future success amidst market challenges.

NeoGenomics reports strong Q3 growth, eyes accelerated breast coverage

NeoGenomics demonstrated robust growth and operational improvements in Q3.
The company's focus on high-value areas like breast cancer is a strategic advantage.
Challenges include potential delays in submissions and ongoing labor inflation concerns.
Opportunities lie in accelerated breast coverage, sales force expansion, and payment efficiency enhancements.

NeoGenomics reports strong Q4 earnings and outlines growth strategies

NeoGenomics delivered strong financial performance in Q4 2023, with revenue growth, improved profitability, and a focus on strategic investments for future growth and operational efficiency.
The company's strengths lie in its strategic focus areas, commitment to value creation, and solid financial position, positioning it well for sustainable success and market leadership.
While facing challenges such as market dynamics and operational hurdles, NeoGenomics has opportunities in expanding market share, product innovation, and strategic partnerships to drive growth and profitability.
Overall, NeoGenomics' performance, strengths, challenges, and opportunities indicate a resilient business poised for continued growth, profitability, and market expansion in the evolving healthcare landscape.

NeoGenomics reports robust Q1 growth, eyes M&A and innovation

NeoGenomics delivered strong financial performance in Q1 2024, driven by revenue growth and operational improvements.
The company's strategic priorities, leadership enhancements, and regulatory outlook bode well for future growth and innovation.
While facing challenges in legal defense and market dynamics, NeoGenomics is well-positioned to leverage opportunities in M&A, product launches, and commercial expansion.

NeoGenomics reports robust Q2 growth amidst legal challenges

NeoGenomics delivered strong financial performance in Q2 2024, with revenue growth, positive adjusted EBITDA, and raised revenue guidance for the year.
The company's strategic focus on innovation, operational efficiency, and growth positions it well to capitalize on the evolving healthcare landscape and increasing demand for advanced diagnostics.
While facing legal challenges, NeoGenomics is actively exploring solutions and remains committed to driving value creation and expanding its market presence through product development and strategic initiatives.

NeoGenomics reports record Q3 earnings, eyes growth through innovation

NeoGenomics delivered strong financial performance in Q3 2024, with record revenues and improved adjusted EBITDA, driven by NGS growth.
The company's strategic focus on sustainable growth, innovation, and financial management strengths position it well for future success.
Challenges lie in addressing profitability evolution, successful Neo Helix integration, and balancing short-term impact with long-term value creation.
Opportunities include Neo Helix development, revenue mix diversification, and achieving the revised adjusted EBITDA guidance range.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , Dec. 12, 2022 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, both dates inclusive (the "Class Period") have until February 6, 2023 to seek appointment as lead plaintiff in the NeoGenomics class action lawsuit. Captioned Goldenberg v.

INVESTOR ALERT: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NEO

New York, New York--(Newsfile Corp. - December 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2023.

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NEO

The mean of analysts' price targets for NeoGenomics (NEO) points to a 40.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should Know

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”).

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NEO)

SAN DIEGO--( BUSINESS WIRE )--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, both dates inclusive (the “Class Period”) have until February 6, 2023 to seek appointment as lead plaintiff in the NeoGenomics class action lawsuit. Captioned Goldenberg v. NeoGenomics, Inc., No. 22-cv-10314 (S.D.N.Y.), the NeoGenomics class action lawsuit charges NeoGenomics and certain of its top executives with violations of the Securities Exchange Act of 1934.

INVESTOR DEADLINE: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – NEO

OAKLAND, Calif.--( BUSINESS WIRE )--Gibbs Law Group announces that it has filed the first and only class action lawsuit against NeoGenomics Inc. (NASDAQ: NEO) and certain of its officers and directors on behalf of investors who purchased NeoGenomics securities from February 27, 2020 through April 26, 2022, inclusive. The lawsuit seeks to recover losses on behalf of NeoGenomics investors under the federal securities laws.

NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors

What started as a seemingly innocuous leadership transition at one of the country's leading molecular diagnostic firms, NeoGenomics, Inc., has evolved into something much more chaotic. After the departure of former NeoGenomics, Inc. CEO and company veteran Douglas VanOort last year, things quickly turned toxic after the abrupt departure of his successor Mark Mallon.

NeoGenomics: What The Leadership Shuffle Means

LOS ANGELES--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”). NeoGenomics investors have until February 6, 2023 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors

Did you lose money on investments in NeoGenomics, Inc.? If so, please visit NeoGenomics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

NEOGENOMICS, INC. (NEO) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against NeoGenomics, Inc. (NEO)

LOS ANGELES, CA / ACCESSWIRE / December 9, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NeoGenomics, Inc. ("NeoGenomics" or "the Company") (NASDAQ:NEO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 27, 2020 and April 26, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before February 6, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Dec. 8, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2023.

ROSEN, A LEADING LAW FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NEO

SAN DIEGO--( BUSINESS WIRE )--The Class: Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, for violations of the Securities Exchange Act of 1934. NeoGenomics provides cancer tests and testing services to doctors, clinics, hospitals, and pharmaceutical companies. Among the Company's portfolio of tests are next generation sequencing (“NGS”) tests.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against NeoGenomics, Inc. (NEO)

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2022.

EQUITY ALERT: Rosen Law Firm Encourages NeoGenomics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – NEO

BENSALEM, Pa.--( BUSINESS WIRE )--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”). NeoGenomics investors have until February 6, 2023 to file a lead plaintiff motion.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors

NEW YORK--( BUSINESS WIRE )--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) securities during the period from February 27, 2020 through April 26, 2022 (the “Class Period”). Investors have until February 6, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of NeoGenomics, Inc. (NEO) Investors

SAN DIEGO--( BUSINESS WIRE )-- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, inclusive (the “Class Period”) have until February 6, 2023 to seek appointment as lead plaintiff in the NeoGenomics class action lawsuit. Captioned Goldenberg v. NeoGenomics, Inc., No. 22-cv-10314 (S.D.N.Y.), the NeoGenomics class action lawsuit charges NeoGenomics and certain of its top executives with violations of the Securities Exchange Act of 1934.

INVESTOR ALERT: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead the NeoGenomics Class Action Lawsuit - NEO

LOS ANGELES, CA / ACCESSWIRE / December 6, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NeoGenomics, Inc. ("NeoGenomics" or "the Company") (NASDAQ:NEO) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 27, 2020 and April 26, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before February 6, 2023.

INVESTOR ACTION DEADLINE: The Schall Law Firm Files Class Action on Behalf of Investors in NeoGenomics, Inc. and Advises Shareholders with Losses of $500,000 to Contact the Firm

OAKLAND, Calif.--( BUSINESS WIRE )--Ninth paragraph, second sentence of release should read: If you suffered a loss in NeoGenomics, you have until February 6, 2023, which is the first business day after 60 days from the date of the publication of this notice, to request that the Court appoint you as lead plaintiff.

CORRECTING and REPLACING NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NeoGenomics, Inc. (“NeoGenomics” or “the Company”) (NASDAQ: NEO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in NeoGenomics, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm

FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Listing Rules, equity inducement awards to Mr. Jeff Sherman, the company's new chief financial officer.

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Privia Health Group

Jeffrey S. Sherman Appointed Chief Financial Officer FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that Jeffrey S.

NeoGenomics Announces Chief Financial Officer Transition

NEO Q3 results carry signs of stability after tumultuous six months, which saw the company running without a CEO. It is too early to assess the performance of the current CEO, given that Q3 results are attributed to the previous interim CEO and her emergency management council.

NeoGenomics: Too Early To Celebrate

Data presented at this year's San Antonio Breast Cancer Symposium builds on strong base of evidence supporting promise of RaDaR in helping prevent recurrence and improving outcomes FT. MYERS, FL / ACCESSWIRE / November 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, and its liquid biopsy-focused subsidiary, Inivata Limited ("Inivata") today announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, support the use of the RaDaR® Assay across all types of early breast cancer in both the adjuvant and surveillance settings.

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

ImmunoGen

Program leverages NeoGenomics' expertise to provide ovarian cancer patients critical insights to ensure they are getting the right treatment FT. MYERS, FL / ACCESSWIRE / November 18, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers (EOC).Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq:IMGN), EOC patients will have access to the FOLR1 IHC CDx test (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to measure the expression of a protein called folate receptor alpha (FRα).

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

The cancer screening company showed its turnaround may be working.

News for NeoGenomics Stock (NEO)